Forum Update: Supporting Community-Led Discussion
The forum was created as a space for shared learning and peer support, and as the community grows, we want to lean more fully into that purpose.
Going forward, PAAB will be taking a more listening-first role in forum discussions. Rather than responding immediately to every question, we’ll be encouraging members to engage with one another, share experiences, and help build collective understanding. PAAB will continue to monitor conversations and will step in to:
- Correct any misunderstandings
- Provide guidance when questions remain unanswered after a few days
- Support discussions where official clarification is needed
Our goal is to foster a collaborative, trusted community where knowledge is shared and strengthened by everyone’s contributions.
Thank you for being part of the conversation.
Generic product launch announcement: can we mention the original brand name?
-
Can a generic company make mention of the original brand name in their launch announcement communication to HCPs? We would like to explore two scenarios: one in which the original brand is no longer manufactured and our communication announces the launch of a generic so that docs can keep their patients on the same pill as the original molecule and a scenario in which the original brand is still available for purchase?
-
This post is deleted!
-
@akar Great question.
Note that any of the proposed content would require review under the PAAB code. This is occasionally a point of confusion in the generic space.
If the generic product’s TMA refers to the innovator brand as the reference product, the generic manufacturer may convey this fact in the APS. For example, “… generic version of Drug X [the reference product]”.
In the unlikely event that the reference product is no longer authorized for sale, this should be conveyed through a cross-reference to the claim above. However, a manufacturer should only discuss the availability status of its own products. For example, it would be unacceptable to comment on a competitor’s drug shortage issues.
Any messages relating to switching will require support from the TMA or standard setting organizations.
